[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Iron Deficiency Anemia Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Therapy Type (Oral Iron Therapy, Parenteral Iron Therapy, Red Blood Cell Transfusion), By End User (Hospitals, Clinics, and Home Healthcare), By Region and Competition.

October 2023 | 173 pages | ID: I765221C3F0DEN
TechSci Research

US$ 4,900.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Global Iron Deficiency Anemia Therapy Market has valued at USD 13.35 billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.72% through 2028. The Global Iron Deficiency Anemia Therapy Market refers to the pharmaceutical and healthcare sector dedicated to the prevention and treatment of iron deficiency anemia, a prevalent medical condition characterized by a deficiency of iron in the body, leading to a decreased number of red blood cells and insufficient oxygen-carrying capacity. This market encompasses a wide range of therapies, medications, and interventions aimed at correcting iron deficiency, increasing red blood cell production, and improving overall patient health. Iron deficiency anemia therapy involves the administration of iron supplements, dietary changes, and, in severe cases, blood transfusions. It is a critical component of healthcare systems globally, addressing a condition that affects millions of individuals, particularly women, children, and individuals in low-resource settings. The market is driven by factors such as the high prevalence of iron deficiency anemia, increased awareness and diagnostics, advancements in therapeutic approaches, and ongoing research and development efforts to improve treatment options. It plays a vital role in enhancing the quality of life for individuals affected by this condition and reducing the associated health risks, making it an integral part of global public health initiatives.

Key Market Drivers

High Prevalence of Iron Deficiency Anemia

The high prevalence of iron deficiency anemia (IDA) serves as a fundamental driver in the Global Iron Deficiency Anemia Therapy Market. IDA is a widespread public health concern, affecting millions of individuals worldwide, regardless of age, gender, or socioeconomic status. This condition arises due to insufficient iron levels in the body, leading to a reduction in red blood cell production and the body's capacity to transport oxygen effectively. IDA is particularly prevalent among certain demographic groups, including women of childbearing age, children, pregnant women, and individuals in low-resource settings. In addition to its health impact, IDA can lead to severe complications, impairing physical and cognitive development in children and increasing the risk of adverse pregnancy outcomes. As a result, healthcare systems globally prioritize the diagnosis and treatment of IDA, driving the demand for iron deficiency anemia therapies. The market responds by offering a range of treatment options, including iron supplementation, dietary recommendations, and, in severe cases, intravenous iron infusions. The persistent high prevalence of IDA underscores the market's significance in addressing this global health challenge, improving the well-being of affected individuals, and reducing the associated economic and healthcare burdens on societies worldwide.

Increased Awareness and Diagnosis

Increased awareness and diagnosis play a pivotal role in propelling the Global Iron Deficiency Anemia (IDA) Therapy Market. Over recent years, there has been a growing recognition of the far-reaching consequences of iron deficiency anemia and the importance of timely intervention. Healthcare providers, advocacy groups, and public health campaigns have heightened awareness among both medical professionals and the general population. This increased awareness has led to more individuals seeking medical evaluation and diagnosis for iron deficiency anemia, even in its early stages. Improved diagnostic tools and methods, such as blood tests measuring hemoglobin and ferritin levels, have made it easier to identify iron deficiency anemia accurately. As a result, individuals at risk, such as pregnant women, children, and individuals with specific medical conditions, are being diagnosed more frequently. This trend translates into a higher demand for iron deficiency anemia therapies, including iron supplements, dietary guidance, and medical interventions. The market responds by offering a diverse range of treatment options, addressing the varying needs of diagnosed individuals. Ultimately, increased awareness and diagnosis not only improve the management of iron deficiency anemia but also contribute to overall public health by reducing the potential for complications associated with untreated or undiagnosed IDA, such as fatigue, cognitive impairments, and adverse pregnancy outcomes

Advancements in Therapeutic Approaches

Advancements in therapeutic approaches are a driving force behind the Global Iron Deficiency Anemia (IDA) Therapy Market. Over the years, significant progress has been made in developing more effective and patient-friendly treatments for IDA. Traditional therapies, such as oral iron supplements, have been improved for better tolerability and reduced side effects, making adherence to treatment regimens more manageable for patients. Additionally, innovative delivery methods like intravenous iron infusions have gained prominence, offering a quicker and more direct way to replenish iron stores, particularly in cases where oral supplements are not well-absorbed or tolerated. Furthermore, research has led to the development of novel iron-based compounds and formulations that enhance iron bioavailability and minimize gastrointestinal side effects. These advancements not only provide healthcare providers with a broader array of treatment options but also improve patient outcomes and satisfaction, fostering greater compliance with prescribed therapies. As a result, the market is evolving to meet the diverse needs of individuals with IDA, ultimately contributing to more effective management and a higher quality of life for those affected by this common nutritional deficiency.

Nutritional Supplements

Nutritional supplements constitute a significant aspect of the Global Iron Deficiency Anemia (IDA) Therapy Market. These supplements play a crucial role in addressing iron deficiency by providing individuals with an accessible and convenient means of increasing their iron intake. Iron is an essential nutrient that can be obtained through dietary sources, including red meat, poultry, fish, and fortified cereals. However, some individuals may struggle to meet their iron requirements through diet alone due to dietary restrictions, limited access to diverse foods, or specific medical conditions that hinder iron absorption. In such cases, nutritional supplements, often in the form of oral iron pills or liquid preparations, become instrumental in ensuring adequate iron intake. These supplements are readily available over-the-counter or as prescribed medications and are a popular preventive and therapeutic measure for individuals at risk of or diagnosed with iron deficiency anemia. They are designed to provide a controlled and easily absorbable source of iron, helping to boost hemoglobin levels, replenish iron stores, and alleviate the symptoms associated with IDA. Nutritional supplements thus contribute significantly to the IDA therapy market, addressing the diverse needs of individuals seeking to improve their iron status and overall health. They are particularly valuable for populations such as pregnant women, infants, and vegetarians, who may require additional iron supplementation to maintain optimal iron levels and prevent anemia.

Key Market Challenges

Side Effects and Tolerability Issues

Side effects and tolerability issues are significant restraining factors within the Global Iron Deficiency Anemia (IDA) Therapy Market. While iron supplementation is an effective treatment for IDA, it often comes with unwelcome gastrointestinal side effects, including nausea, constipation, diarrhea, stomach cramps, and a metallic taste in the mouth. These side effects can lead to poor patient compliance, as individuals may discontinue treatment due to discomfort. Furthermore, some patients may find it difficult to tolerate high-dose iron supplements, leading to incomplete courses of therapy and suboptimal outcomes. The challenge lies in finding a balance between providing an effective iron therapy and minimizing side effects. This has spurred research and development efforts to create iron supplements with improved tolerability profiles, including slow-release formulations, alternative iron salts, and combination therapies with agents that mitigate side effects. Ensuring that patients are aware of potential side effects, managing them effectively when they occur, and offering alternative therapies when necessary are essential steps in addressing this challenge and enhancing the overall success of IDA therapy programs.

Interference with Medications and Dietary Components

Interference with medications and dietary components represents a significant challenge in the Global Iron Deficiency Anemia (IDA) Therapy Market. Iron supplements, which are commonly used to treat IDA, can interact with certain medications and dietary elements, potentially compromising treatment efficacy and patient safety. For instance, iron can interfere with the absorption of medications like antibiotics, thyroid hormones, and certain antacids, reducing their effectiveness. Conversely, some medications, such as proton pump inhibitors and calcium supplements, can hinder the absorption of iron. Moreover, dietary components like tannins in tea, phytates in whole grains, and calcium-rich foods can inhibit iron absorption when consumed concurrently with iron supplements or iron-rich foods. These interactions necessitate careful consideration by healthcare providers when prescribing iron therapy, as adjustments to medication regimens and dietary advice may be required to optimize treatment outcomes. Overcoming this challenge involves educating both patients and healthcare professionals about potential interactions, implementing personalized treatment plans, and, in some cases, considering alternative iron supplementation methods or formulations that minimize interference while ensuring adequate iron intake. Solving this issue not only enhances the effectiveness of IDA therapy but also reduces the risk of medication inefficacy and adverse reactions due to interactions, ultimately improving patient care and satisfaction.

Key Market Trends

Intravenous Iron Therapies

Intravenous (IV) Iron Therapies represent a notable trend in the Global Iron Deficiency Anemia (IDA) Therapy Market. These therapies involve the administration of iron directly into the bloodstream through an IV infusion, offering an alternative to traditional oral iron supplements. IV iron therapies have gained prominence for several reasons. Firstly, they provide a more rapid and efficient means of replenishing iron stores, making them particularly suitable for individuals with severe IDA or those who cannot tolerate oral supplements due to gastrointestinal side effects. Secondly, IV iron therapies offer predictable and controlled dosing, ensuring that patients receive the necessary iron without variability in absorption seen with oral supplements. Moreover, IV iron treatments are often preferred during certain medical conditions or surgeries where rapid correction of anemia is essential. As a result, pharmaceutical companies are developing a range of IV iron formulations with improved safety profiles and reduced risk of adverse reactions, contributing to their increasing adoption. This trend reflects a shift towards more patient-centered care and personalized treatment plans, as healthcare providers consider the individual needs and preferences of patients when selecting the most appropriate iron supplementation method, ultimately enhancing the effectiveness and tolerability of IDA therapy.

Nutritional Guidance

Nutritional guidance is a significant trend within the Global Iron Deficiency Anemia (IDA) Therapy Market, emphasizing the importance of dietary strategies in managing and preventing IDA. Healthcare providers are increasingly incorporating nutritional counseling and education into IDA treatment plans. This guidance involves recommending iron-rich foods, such as lean meats, poultry, fish, beans, and fortified cereals, to patients as part of a comprehensive approach to improving their iron intake. Moreover, dietary advice includes suggestions on optimizing iron absorption, such as pairing iron-rich foods with sources of vitamin C, which enhances iron absorption. This trend reflects a growing recognition that IDA therapy should extend beyond pharmacological interventions, with dietary choices playing a crucial role in overall treatment effectiveness. For individuals who may not require medication or prefer dietary approaches, this guidance empowers them to make informed choices to increase their iron intake naturally. Additionally, nutritional guidance is particularly relevant for vulnerable populations, such as pregnant women and children, who have higher iron requirements. By focusing on dietary strategies alongside traditional treatments, healthcare providers aim to enhance patient outcomes, reduce the risk of recurrent IDA, and promote long-term iron sufficiency, ultimately improving the overall quality of care for individuals affected by this common nutritional deficiency.

Segmental Insights

Therapy Type Insights

In 2022, the Iron Deficiency Anemia Therapy Market was dominated by the Oral Iron Therapy segment and is predicted to continue expanding over the coming years. This is attributed due to the rising prevalence of deficiency of iron especially in women, and its convenience, cost-effectiveness, and non-invasiveness.

Regional Insights

In 2022, the Global Iron Deficiency Anemia Therapy Market was dominated by the North America segment and is predicted to continue expanding over the coming years. This is ascribed due to rising anemia cases, rising development of technology, and the growing healthcare infrastructure.

Key Market Players

Pharmacosmos AS

AMAG Pharmaceuticals Inc.

Sanofi SA

AbbVie Inc.

Fresenius SE & Co. KGaA

Keryx Biopharmaceuticals Inc.

Akebia Therapeutics.,

Allergan PLC

Pieris Pharmaceuticals Inc.

Report Scope:

In this report, the Global Iron Deficiency Anemia Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
  • Global Iron Deficiency Anemia Therapy Market, By Therapy Type:
  • Oral Iron Therapy
  • Parenteral Iron Therapy
  • Red Blood Cell Transfusion
  • Global Iron Deficiency Anemia Therapy Market, By End User:
  • Hospitals
  • Clinics
  • Home Healthcare
  • Global Iron Deficiency Anemia Therapy Market, By Region:
  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt
Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Iron Deficiency Anemia Therapy Market.

Available Customizations:

Global Iron Deficiency Anemia Therapy Market report with the given Market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information
  • Detailed analysis and profiling of additional Market players (up to five).
1. PRODUCT OVERVIEW

1.1. Market Definition
1.2. Scope of the Market
  1.2.1. Markets Covered
  1.2.2. Years Considered for Study
  1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Types
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends

4. VOICE OF CUSTOMER

5. GLOBAL IRON DEFICIENCY ANEMIA THERAPY MARKET OUTLOOK

5.1. Market Size & Forecast
  5.1.1. By Value
5.2. Market Share & Forecast
  5.2.1. By Therapy Type (Oral Iron Therapy, Parenteral Iron Therapy, Red Blood Cell Transfusion)
  5.2.2. By End User (Hospitals, Clinics, and Home Healthcare)
  5.2.3. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
  5.2.4. By Company (2022)
5.3. Product Market Map
  5.3.1. By Therapy Type
  5.3.2. By End User
  5.3.3. By Region

6. NORTH AMERICA IRON DEFICIENCY ANEMIA THERAPY MARKET OUTLOOK

6.1. Market Size & Forecast
  6.1.1. By Value
6.2. Market Share & Forecast
  6.2.1. By Therapy Type
  6.2.2. By End User
  6.2.3. By Country
6.3. North America: Country Analysis
  6.3.1. United States Iron Deficiency Anemia Therapy Market Outlook
    6.3.1.1. Market Size & Forecast
      6.3.1.1.1. By Value
    6.3.1.2. Market Share & Forecast
      6.3.1.2.1. By Therapy Type
      6.3.1.2.2. By End User
  6.3.2. Canada Iron Deficiency Anemia Therapy Market Outlook
    6.3.2.1. Market Size & Forecast
      6.3.2.1.1. By Value
    6.3.2.2. Market Share & Forecast
      6.3.2.2.1. By Therapy Type
      6.3.2.2.2. By End User
  6.3.3. Mexico Iron Deficiency Anemia Therapy Market Outlook
    6.3.3.1. Market Size & Forecast
      6.3.3.1.1. By Value
    6.3.3.2. Market Share & Forecast
      6.3.3.2.1. By Therapy Type
      6.3.3.2.2. By End User

7. EUROPE IRON DEFICIENCY ANEMIA THERAPY MARKET OUTLOOK

7.1. Market Size & Forecast
  7.1.1. By Value
7.2. Market Share & Forecast
  7.2.1. By Therapy Type
  7.2.2. By End User
  7.2.3. By Country
7.3. Europe: Country Analysis
  7.3.1. Germany Iron Deficiency Anemia Therapy Market Outlook
    7.3.1.1. Market Size & Forecast
      7.3.1.1.1. By Value
    7.3.1.2. Market Share & Forecast
      7.3.1.2.1. By Therapy Type
      7.3.1.2.2. By End User
  7.3.2. France Iron Deficiency Anemia Therapy Market Outlook
    7.3.2.1. Market Size & Forecast
      7.3.2.1.1. By Value
    7.3.2.2. Market Share & Forecast
      7.3.2.2.1. By Therapy Type
      7.3.2.2.2. By End User
  7.3.3. United Kingdom Iron Deficiency Anemia Therapy Market Outlook
    7.3.3.1. Market Size & Forecast
      7.3.3.1.1. By Value
    7.3.3.2. Market Share & Forecast
      7.3.3.2.1. By Therapy Type
      7.3.3.2.2. By End User
  7.3.4. Italy Iron Deficiency Anemia Therapy Market Outlook
    7.3.4.1. Market Size & Forecast
      7.3.4.1.1. By Value
    7.3.4.2. Market Share & Forecast
      7.3.4.2.1. By Therapy Type
      7.3.4.2.2. By End User
  7.3.5. Spain Iron Deficiency Anemia Therapy Market Outlook
    7.3.5.1. Market Size & Forecast
      7.3.5.1.1. By Value
    7.3.5.2. Market Share & Forecast
      7.3.5.2.1. By Therapy Type
      7.3.5.2.2. By End User

8. ASIA-PACIFIC IRON DEFICIENCY ANEMIA THERAPY MARKET OUTLOOK

8.1. Market Size & Forecast
  8.1.1. By Value
8.2. Market Share & Forecast
  8.2.1. By Therapy Type
  8.2.2. By End User
  8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
  8.3.1. China Iron Deficiency Anemia Therapy Market Outlook
    8.3.1.1. Market Size & Forecast
      8.3.1.1.1. By Value
    8.3.1.2. Market Share & Forecast
      8.3.1.2.1. By Therapy Type
      8.3.1.2.2. By End User
  8.3.2. Japan Iron Deficiency Anemia Therapy Market Outlook
    8.3.2.1. Market Size & Forecast
      8.3.2.1.1. By Value
    8.3.2.2. Market Share & Forecast
      8.3.2.2.1. By Therapy Type
      8.3.2.2.2. By End User
  8.3.3. India Iron Deficiency Anemia Therapy Market Outlook
    8.3.3.1. Market Size & Forecast
      8.3.3.1.1. By Value
    8.3.3.2. Market Share & Forecast
      8.3.3.2.1. By Therapy Type
      8.3.3.2.2. By End User
  8.3.4. South Korea Iron Deficiency Anemia Therapy Market Outlook
    8.3.4.1. Market Size & Forecast
      8.3.4.1.1. By Value
    8.3.4.2. Market Share & Forecast
      8.3.4.2.1. By Therapy Type
      8.3.4.2.2. By End User
  8.3.5. Australia Iron Deficiency Anemia Therapy Market Outlook
    8.3.5.1. Market Size & Forecast
      8.3.5.1.1. By Value
    8.3.5.2. Market Share & Forecast
      8.3.5.2.1. By Therapy Type
      8.3.5.2.2. By End User

9. SOUTH AMERICA IRON DEFICIENCY ANEMIA THERAPY MARKET OUTLOOK

9.1. Market Size & Forecast
  9.1.1. By Value
9.2. Market Share & Forecast
  9.2.1. By Therapy Type
  9.2.2. By End User
  9.2.3. By Country
9.3. South America: Country Analysis
  9.3.1. Brazil Iron Deficiency Anemia Therapy Market Outlook
    9.3.1.1. Market Size & Forecast
      9.3.1.1.1. By Value
    9.3.1.2. Market Share & Forecast
      9.3.1.2.1. By Therapy Type
      9.3.1.2.2. By End User
  9.3.2. Argentina Iron Deficiency Anemia Therapy Market Outlook
    9.3.2.1. Market Size & Forecast
      9.3.2.1.1. By Value
    9.3.2.2. Market Share & Forecast
      9.3.2.2.1. By Therapy Type
      9.3.2.2.2. By End User
  9.3.3. Colombia Iron Deficiency Anemia Therapy Market Outlook
    9.3.3.1. Market Size & Forecast
      9.3.3.1.1. By Value
    9.3.3.2. Market Share & Forecast
      9.3.3.2.1. By Therapy Type
      9.3.3.2.2. By End User

10. MIDDLE EAST AND AFRICA IRON DEFICIENCY ANEMIA THERAPY MARKET OUTLOOK

10.1. Market Size & Forecast
  10.1.1. By Value
10.2. Market Share & Forecast
  10.2.1. By Therapy Type
  10.2.2. By End User
  10.2.3. By Country
10.3. MEA: Country Analysis
  10.3.1. UAE Iron Deficiency Anemia Therapy Market Outlook
    10.3.1.1. Market Size & Forecast
      10.3.1.1.1. By Value
    10.3.1.2. Market Share & Forecast
      10.3.1.2.1. By Therapy Type
      10.3.1.2.2. By End User
  10.3.2. Saudi Arabia Iron Deficiency Anemia Therapy Market Outlook
    10.3.2.1. Market Size & Forecast
      10.3.2.1.1. By Value
    10.3.2.2. Market Share & Forecast
      10.3.2.2.1. By Therapy Type
      10.3.2.2.2. By End User
  10.3.3. South Africa Iron Deficiency Anemia Therapy Market Outlook
    10.3.3.1. Market Size & Forecast
      10.3.3.1.1. By Value
    10.3.3.2. Market Share & Forecast
      10.3.3.2.1. By Therapy Type
      10.3.3.2.2. By End User

11. MARKET DYNAMICS

11.1. Drivers
11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

12.1. Merger & Acquisition
12.2. Product Development
12.3. Recent Developments

13. COMPETITIVE LANDSCAPE

13.1. Business Overview
13.2. Company Snapshot
13.3. Products & Services
13.4. Financials (As Reported)
13.5. Recent Developments
  13.5.1. Pharmacosmos AS
  13.5.2. AMAG Pharmaceuticals Inc.
  13.5.3. Sanofi SA
  13.5.4. AbbVie Inc.
  13.5.5. Fresenius SE & Co. KGaA
  13.5.6. Keryx Biopharmaceuticals Inc.
  13.5.7. Akebia Therapeutics.,
  13.5.8. Allergan PLC
  13.5.9. Pieris Pharmaceuticals Inc.

14. STRATEGIC RECOMMENDATIONS


More Publications